HIV/AIDS

The Department of Health has begun distributing the injectable through an initial network of 360 health facilities located in high-burden districts.

The launch brings together national and international health stakeholders who are supporting Nigeria’s broader HIV response strategy.

The tablet combines 100 mg of doravirine and 0.25 mg of islatravir in a once-daily formulation.

Lenacapavir complements existing prevention methods such as oral pre-exposure prophylaxis and long-acting injectable cabotegravir.

The Global Fund has provided USD 3 million for governance and capacity building, along with USD701 million in programmatic funding.

WHO’s Regional Validation Committee assessed Denmark in June 2025, followed by the Global Validation Advisory Committee in August 2025.

The initial rollout will target 152 health facilities across 15 high-burden counties, following a carefully structured, phased approach.

The transaction marks the end of Pfizer’s involvement with ViiV Healthcare, as the American pharmaceutical giant sells its entire 11.7% stake in the company.

The introduction of lenacapavir will expand rather than replace current prevention methods available in Rwanda.